AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 24870737
Drug: Combination group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination group (pemetrexed + bevacizumab)
Trial: 2037712
Drug: CMT 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMT 1.5 g orally every 12 hours
Trial: 2037712
Drug: CMT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CMT plus sucralfate 1 g orally every 6 hours
Trial: 31443220
Drug: Caffeine 9
RxNorm normalized name: multivit,calcium,min/ferrous fum/folic acid/guarana/caffeine 9 mg iron-400 mcg-200 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine 9 mg/kg/b.m. (CAF-9)
Trial: 18042082
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine pre-bed with soluble morning insulin
Trial: 18042082
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine pre-bed with soluble + NPH morning insulin
Trial: 18042082
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine pre-bed with aspart + NPH morning insulin
Trial: 14982565
Drug: Gabapentin 1200
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 1200 mg before surgery, followed by 600 mg at 8, 16, and 24 hours postoperatively
Trial: 6958478
Drug: Budesonide 200
RxNorm normalized name: budesonide 200 mcg/inh inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 200 micrograms twice daily
Trial: 3055745
Drug: Mobilisin ointment
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mobilisin ointment
Trial: 15370901
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg ondansetron
Trial: 8281592
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg ondansetron
Trial: 7978398
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg ondansetron
Trial: 26403472
Drug: Placebo chewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo chewing tablets (identical tablets without bacteria)
Trial: 16707070
Drug: Injection sclerotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection sclerotherapy (compared with conservative treatment)
Trial: 15086644
Drug: Rofecoxib 12.5
RxNorm normalized name: rofecoxib 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib 12.5 mg once a day
Trial: 15086644
Drug: Nabumetone 1,000
RxNorm normalized name: nabumetone 1,000 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabumetone 1,000 mg once a day
Trial: 11710708
Drug: Efficacy parameters
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efficacy parameters of MTX treatment
Trial: 9385480
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) 800 mg/d
Trial: 9385480
Drug: Zidovudine (ZDV)
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine (ZDV) 500 mg/d
Trial: 3300312
Drug: Parenteral agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral agents
Trial: 28634056
Drug: Extracorporeal Shock
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal Shock Wave Therapy (ESWT) administered in 3 sessions with an energy flux density of 0.2, 0.4, and 0.6 mJ/mm2 (low, moderate, high intensity)
Trial: 25926415
Drug: Protein supplementation
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein supplementation (27.5 g of protein, 15 g of carbohydrate, and 0.1 g of fat every night before sleep)
Trial: 9068738
Drug: Itraconazole pulse
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole pulse therapy, 400 mg daily 1 week per month for 3 months
Trial: 3816530
Drug: Dose increase
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose increase condition
Trial: 29326296
Drug: Intrathecal baclofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal baclofen therapy (ITB)
Trial: 25493129
Drug: 4S technique
RxNorm normalized name: 4S,6S-dorzolamide
DrugBank: Dorzolamide (DB00869)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4S technique by emergency medicine residents (EMRs)
Trial: 17366357
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with normal LDL cholesterol concentrations (<3.36 mmol/L)
Trial: 9796505
Drug: Treatment control
RxNorm normalized name: SALICYLIC ACID 2 g in 100 mL TOPICAL LOTION [Lqd ACNE BLEMISH TREATMENT control]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment control (distilled water)
Trial: 811319
Drug: Tetracycline 250
RxNorm normalized name: tetracycline 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline 250 mg four times a day for 14 days
Trial: 811319
Drug: Deteclo 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deteclo 300 mg three times a day for 3 weeks
Trial: 811319
Drug: Tetracycline 250
RxNorm normalized name: tetracycline 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetracycline 250 mg four times a day for 4 days
Trial: 18042892
Drug: Ropivacaine 0.5%
RxNorm normalized name: ROPivacaine 0.5% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.5% (30 mL)
Trial: 14601471
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium supplementation (Slow‐Mag B6) at 320 mg/day
Trial: 14601471
Drug: Patients treated
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients treated with diuretics
Trial: 14601471
Drug: Patients treated
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients treated with Ca channel blockers
Trial: 14601471
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium supplementation (Slow‐Mag B6)
Trial: 10467795
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg nalbuphine
Trial: 10467795
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg nalbuphine
Trial: 10467795
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg nalbuphine
Trial: 8648205
Drug: rgp160 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rgp160 vaccine
Trial: 1995718
Drug: recombinant hepatitis
RxNorm normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recombinant hepatitis B vaccine
Trial: 19436745
Drug: Mebendazole treatment
RxNorm normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mebendazole treatment every 3 months
Trial: 19436745
Drug: Mebendazole treatment
RxNorm normalized name: Mebendazole
DrugBank: Mebendazole (DB00643)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mebendazole treatment
Trial: 2195579
Drug: Caffeine (3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (3.5 mg/kg)
Trial: 31418022
Drug: 30 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 µg RSV-PreF vaccine
Trial: 31418022
Drug: 60 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 µg RSV-PreF vaccine
Trial: 31418022
Drug: 120 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 µg RSV-PreF vaccine
Trial: 29351542
Drug: Anti-adhesion gel
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-adhesion gel (hyaluronic acid-carboxymethylcellulose, Seprafilm®) applied locally during surgery
Trial: 29351542
Drug: No anti-adhesion
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anti-adhesion gel applied (control group)
Trial: 26147178
Drug: Illustrated leaflet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Illustrated leaflet and verbal instructions on oral hygiene and utilization habits
Trial: 1351538
Drug: Perioperative chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perioperative chemotherapy (PeCT)
Trial: 7952453
Drug: Expanded polytetrafluoroethylene
RxNorm normalized name: polytetrafluoroethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expanded polytetrafluoroethylene (ePTFE) patch
Trial: 31797385
Drug: Psychosocial stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosocial stimulation intervention with weekly home visits for 18 months
Trial: 16717329
Drug: Erythromycin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (250 mg infusion)
Trial: 27926661
Drug: Placebo (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline infusion)
Trial: 16717329
Drug: Control (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (saline infusion with 37 degrees C water immersion)
Trial: 24745637
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment uniforms (Control)
Trial: 21949754
Drug: Lopinavir/ritonavir monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir monotherapy
Trial: 20843990
Drug: Current combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current combined antiretroviral treatment (cART)
Trial: 20843990
Drug: Lopinavir/ritonavir monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir monotherapy (with treatment intensification)
Trial: 19042197
Drug: Texas Christian
RxNorm normalized name: influenza A virus A/Texas/50/2012 (H3N2) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Texas Christian University‐Treatment Motivation Assessment (TCU‐TMA)
Trial: 16029399
Drug: ROC 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ROC 0.25 mg.kg(‐1)
Trial: 10499748
Drug: 3 mL
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mL 1.5% lidocaine plus epinephrine 15 microg (1/200,000)
Trial: 10499748
Drug: 3 mL
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mL normal saline
Trial: 1800468
Drug: Epidural fentanyl,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural fentanyl, 5 micrograms/mL
Trial: 1800468
Drug: Epidural fentanyl,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural fentanyl, 5 micrograms/mL with 0.75% solution of lidocaine
Trial: 31007108
Drug: Cervicitis agents
RxNorm normalized name: CERVICAL CAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cervicitis agents screening using multiplex PCR
Trial: 9690805
Drug: Evening subcutaneous
RxNorm normalized name: Evenity
DrugBank: Romosozumab (DB11866)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Evening subcutaneous administration of 5000 IU dalteparin
Trial: 9690805
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of 5000 IU dalteparin
Trial: 9690805
Drug: Subcutaneous administration
RxNorm normalized name: subcutaneous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous administration of 2500 IU dalteparin
Trial: 796939
Drug: Ketoprofen 200
RxNorm normalized name: ketoprofen 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 200 mg daily for 4 weeks
Trial: 796939
Drug: Phenylbutazone 300
RxNorm normalized name: phenylbutazone 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylbutazone 300 mg daily for 4 weeks
Trial: 31444669
Drug: Low-frequency sonophoresis
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-frequency sonophoresis of Chinese medicine (LFS/CM) combined with intrapleural IL-2
Trial: 31444669
Drug: Low-frequency sonophoresis
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-frequency sonophoresis of Chinese medicine (LFS/CM)
Trial: 31444669
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of IL-2 (control group)
Trial: 17886213
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with ACE‐i
Trial: 17886213
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with ACE‐i + ARB
Trial: 14996515
Drug: Epinastine hydrochloride
RxNorm normalized name: Epinastine Hydrochloride
DrugBank: Epinastine (DB00751)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epinastine hydrochloride 0.05% ophthalmic solution, 1 drop/eye BID for 8 weeks
Trial: 14996515
Drug: Levocabastine hydrochloride
RxNorm normalized name: Levocabastine Hydrochloride
DrugBank: Levocabastine (DB01106)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levocabastine hydrochloride 0.05% ophthalmic suspension, 1 drop/eye BID for 8 weeks
Trial: 7884660
Drug: TY‐11345 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TY‐11345 (40 mg single dose)
Trial: 7884660
Drug: TY‐11345 (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TY‐11345 (20 mg single dose)
Trial: 7884660
Drug: TY‐11345 (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TY‐11345 (60 mg repeated dose)
Trial: 7884660
Drug: TY‐11345 (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TY‐11345 (40 mg single dose with food)
Trial: 7884660
Drug: TY‐11345 (20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TY‐11345 (20, 40, and 80 mg single doses)
Trial: 7884660
Drug: TY‐11345 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TY‐11345 (all doses)
Trial: 2889217
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg terfenadine twice daily
Trial: 2569998
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg chlorpheniramine three times daily
Trial: 30176758
Drug: Intrauterine misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrauterine misoprostol (400 mg) added to oxytocin
Trial: 26300016
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (NaHCO3) 0.3 g.kg(‐1) body weight
Trial: 23273683
Drug: Thoracic epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thoracic epidural infusion (PERI group)
Trial: 16849754
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g EPA
Trial: 16849754
Drug: 4 g
RxNorm normalized name: CTX4 Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g EPA
Trial: 12845488
Drug: Furosemide 40
RxNorm normalized name: furosemide 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide 40 mg/day orally for 5 days
Trial: 30939537
Drug: Transdermal 17Î²-estradiol
RxNorm normalized name: Estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal 17Î²-estradiol (t-E2)
Trial: 30341117
Drug: Single FMT
RxNorm normalized name: [18F]FMT
DrugBank: 6-[18F]-Fluoro-L-m-tyrosine (DB17621)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single FMT dose
Trial: 30341117
Drug: Five daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five daily FMT doses
Trial: 30341117
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no FMT dose)
Trial: 20560847
Drug: Internet-based clinician-assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based clinician-assisted cognitive behavioural treatment program (the Panic program)
Trial: 16900557
Drug: Biologic treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic treatments
Trial: 16900557
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy or placebo
Trial: 16195955
Drug: Later sessions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Later sessions (regardless of drug condition)
Trial: 17398191
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no antihypertensive therapy)
Trial: 15021311
Drug: IFN alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IFN alfa-2b 3 mIU daily plus RBV 800 mg/d
Trial: 15021311
Drug: IFN alfa-2b
RxNorm normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IFN alfa-2b 3 mIU thrice weekly plus RBV 800 mg/d
Trial: 7984652
Drug: 10% naproxen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% naproxen gel
Trial: 2257959
Drug: 10% ketoprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% ketoprofen gel
Trial: 519265
Drug: Fibrinolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinolytic therapy (streptokinase)
Trial: 519265
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no fibrinolytic therapy)
Trial: 23676183
Drug: CETP inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CETP inhibitor
Trial: 19396791
Drug: 1.25 mg
RxNorm normalized name: menthol 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25 mg intracameral bevacizumab (Group 1)
Trial: 19396791
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg intracameral bevacizumab (Group 2)
Trial: 16525571
Drug: Eptifibatide plus
RxNorm normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eptifibatide plus unfractionated heparin
Trial: 30146709
Drug: BTL UNISON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTL UNISON device treatments (4 sessions)
Trial: 30146709
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatments)
Trial: 17984433
Drug: 3.86% glucose,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.86% glucose, low pH/high GDP dialysis solution (pH 5.5)
Trial: 10446037
Drug: 400 mg/day
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/day of alpha-tocopherol
Trial: 7796786
Drug: 30 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/day zinc gluconate for 3 months
Trial: 30430745
Drug: Mechanical bowel
RxNorm normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mechanical bowel preparation (MBP) using either two bottles of sodium phosphate or 2-L polyethylene glycol
Trial: 22976604
Drug: No mechanical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No mechanical bowel preparation (no-MBP)
Trial: 28561902
Drug: Rapid BDM
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid BDM (ready-to-dilute solution, 50 mL admixture, infusion time 10 minutes)
Trial: 28561902
Drug: Original BDM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original BDM (lyophilized product requiring reconstitution, 500 mL admixture, infusion time 30 or 60 minutes)
Trial: 28561902
Drug: Both BDM
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both BDM formulations
Trial: 24621834
Drug: Intravenous levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous levosimendan for 24 hours
Trial: 17473298
Drug: Intravenous levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous levosimendan
Trial: 21656668
Drug: high in
RxNorm normalized name: High incidence antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high in iTFA (10.2 g/2500 kcal)
Trial: 19303414
Drug: lamivudine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lamivudine (100 mg daily)
Trial: 28342988
Drug: Intervention group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention group (IG) received culinary-based workshops, monthly newsletters, and telephone calls incorporating Motivational Interviewing.
Trial: 28342988
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (CG) received monthly nutritional brochures from the American Institute for Cancer Research.
Trial: 26056183
Drug: Paclitaxel with
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel with bevacizumab (90 mg/m2)